drugset

drugset / Trial / NCT00191204

Open Label Phase III Duloxetine Study for Stress Urinary Incontinence

NCT00191204 ↗

Phase 3 Completed 363 enrolled Eli Lilly and Company Boehringer Ingelheim · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to monitor the long term safety of duloxetine in the treatment of stress urinary incontinence.

Timeline

Start: 2001-09
Primary completion: —
Completion: 2006-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duloxetine	Small molecule	—	—

Indications